Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia
about
Skin toxicity in a patient with ovarian cancer treated with pegylated liposomal doxorubicin: A case report and review of the literatureIncidence and implications of chemotherapy related hand-foot syndrome.Multikinase Inhibitor-Induced Hand-Foot Skin Reaction: A Review of Clinical Presentation, Pathogenesis, and Management.Evaluation and treatment of chemotherapy extravasation injuries.Liposomal cancer chemotherapy: current clinical applications and future prospects.Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome).Anticancer drug induced palmar plantar erythrodysesthesiaTroxacitabine-based therapy of refractory leukemia.Liposomally targeted cytotoxic drugs for the treatment of cancer.Prophylactic pyridoxine was not able to reduce the incidence of capecitabine-induced hand-foot syndrome: A meta-analysis.Intertriginous epidermal dysmaturation from pegylated liposomal doxorubicin.Doxorubicin encapsulated in stealth liposomes conferred with light-triggered drug release.Optimal therapy for platinum-resistant recurrent ovarian cancer: doxorubicin, gemcitabine or topotecan?Troxacitabine in leukemia.Docetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review.The use of cod liver oil by patients receiving pegylated liposomal doxorubicin is associated with a lack of severe palmar-plantar erythrodysesthesia.Evaluation of pegylated liposomal doxorubicin dose on the adverse drug event profile and outcomes in treatment of recurrent endometrial cancer.Pharmacokinetic and toxicity considerations for the use of anthracyclines in ovarian cancer treatment.Pegylated liposomal doxorubicin in ovarian cancer.Palmar-plantar erythrodysesthesia syndrome associated with liposomal daunorubicin.Pegylated liposomal doxorubicin: tolerability and toxicity.[Hand-foot syndrome with tyrosine kinase inhibitor therapy: treatment recommendations].
P2860
Q28468353-9B62DA83-032A-4A12-9E9E-968B600CFF0EQ30244770-F65E85AA-33CC-4C28-AD1F-9671E69E1B6BQ30250106-13D1401A-0441-4591-9C8A-600D4D18DDC0Q34005497-79183B6E-BEDA-4251-9E29-7C5415C7F324Q34481466-6D275189-A68D-45B5-AF14-0ABD87E288CEQ34488678-054AEFD3-6EF4-4326-B42B-FCC213B61567Q34574145-56C7F33B-6F5E-42CD-8251-9DF31FE44256Q34618110-EC0365D2-6284-4041-B08E-20B2F9084E59Q34734015-91342BF1-230C-4D98-9C49-C1CDA612B9F6Q35051019-E7E4AA5C-5125-4DFF-9713-1272A0523E39Q35125646-CB309D07-D377-43A6-964E-86EECBA9B9D9Q35542453-BA42185A-9AC3-413D-8A92-EFE2249F6876Q36278952-6E5B77C9-C8CD-4A20-BC3C-FEAE7CA88845Q36488198-E3DB5FE8-7FCB-4C07-BA8F-D66E7A724D53Q36868592-03C1647B-2CFC-4395-B532-9D1586E979EFQ37161450-9DE36498-21F5-4845-8460-5B678DE1BF18Q37401589-AC93A5BF-A0F1-4544-ABDF-494523B7BC99Q37507842-AC181092-707A-4C6B-AC28-8C9009B29FACQ37857281-00F77218-3438-4FBD-A07B-2ECE5DA51F93Q43065300-1E4EDEA0-EF49-43AA-984B-563181378B26Q43508321-B77A70CC-B37D-4B58-919D-4A014ECE2FD7Q43636340-5D0C7EBD-0C98-4B47-AC09-010A2BCC9D66Q44020739-6439BB00-1FCF-43B6-AFF7-2D13DAC694DF
P2860
Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia
description
1999 nî lūn-bûn
@nan
1999 թուականին հրատարակուած գիտական յօդուած
@hyw
1999 թվականին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Topical DMSO treatment for peg ...... mar-plantar erythrodysesthesia
@ast
Topical DMSO treatment for peg ...... mar-plantar erythrodysesthesia
@en
Topical DMSO treatment for peg ...... mar-plantar erythrodysesthesia
@nl
type
label
Topical DMSO treatment for peg ...... mar-plantar erythrodysesthesia
@ast
Topical DMSO treatment for peg ...... mar-plantar erythrodysesthesia
@en
Topical DMSO treatment for peg ...... mar-plantar erythrodysesthesia
@nl
prefLabel
Topical DMSO treatment for peg ...... mar-plantar erythrodysesthesia
@ast
Topical DMSO treatment for peg ...... mar-plantar erythrodysesthesia
@en
Topical DMSO treatment for peg ...... mar-plantar erythrodysesthesia
@nl
P2093
P356
P1476
Topical DMSO treatment for peg ...... mar-plantar erythrodysesthesia
@en
P2093
P2888
P356
10.1007/S002800050981
P407
P577
1999-01-01T00:00:00Z
P5875
P6179
1044175142